Grommets (Ventilation Tubes) for Hearing Loss Associated with Otitis Media with Effusion In Children

Brook I . Microbiology and antimicrobial management of sinusitis J Laryngol Otol 2005;119:251–8

Piccirillo JF . Clinical practice. Acute bacterial sinusitis N Engl J Med 2004;351:902–10

Rybak MJ . Increased bacterial resistance: PROTEKT US—an update Ann Pharmacother 2004;38 (9 Suppl):S8–S13

Ip S Fu L Balk E . Update on acute bacterial rhinosinusitis. Evidence Report/Technology Assessment No. 124. (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022). AHRQ Publication No 05-E020-2. Rockville, MD: Agency for Healthcare Research and Quality; 2005.

Anon JB Jacobs MR Poole MD . Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Otolaryngol Head Neck Surg 2004;130 (1 Suppl):1–45

Sande MA Gwaltney JM . Acute community-acquired bacterial sinusitis: continuing challenges and current management Clin Infect Dis 2004;39(Suppl)3:S151–S8

Poole MD . Acute bacterial rhinosinusitis: clinical impact of resistance and susceptibility Am J Med 2004;117 (Suppl 3A):29S–38S

Woodcock JM Andrews JM Brenwald NP . The in-vitro activity of faropenem, a novel oral penem J Antimicrob Chemother 1997;39:35–43

Critchley IA Karlowsky JA Draghi DC . Activities of faropenem, an oral beta-lactam, against recent U.S isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 2002;46:550–5

Jones ME Blosser-Middleton RS Critchley IA . Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents J Antimicrob Chemother 2003;51:196–9

du Plessis M Capper TP Klugman KP . In vitro activity of faropenem against respiratory pathogens J Antimicrob Chemother 2002;49:575–7

Inoue E Mitsuhashi S . In vitro antibacterial activity and beta-lactamase stability of SY555, a new oral penem antibiotic Antimicrob Agents Chemother 1994;38:1974–9

Singh S Echols R . Prospective, multi-center, nonblind, uncontrolled trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days in the treatment of acute bacterial sinusitis (ABS). Study 100287. Proceeding of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, Abstract L-574, 2005.

Food and Drug Administration. FDA Guidance for Industry. Acute bacterial sinusitis—developing antimicrobial drugs for treatment, July 1998. Bethesda, MD: Center for Drug Evaluation and Research; 1998.

Dmitrienko A Offen W Westfall P . Gatekeeping strategies for clinical trials that do not require all primary effects to be significant Stat Med 2003;22:2387–400

Julious SA . Tutorial in biostatistics: sample sizes for clinical trials with normal data Stat Med 2004;23:1921–86

Morikawa T Yoshida M . A useful testing strategy in phase III trials: combined test of superiority and test of equivalence J Biopharmaceut Stat 1995;5:297–306

Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority. The European Agency for the Evaluation of Medicinal Products; 2000, London, UK

Siegert R Berg O Gehanno P . Comparison of the efficacy and safety of faropenem medoxomil and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults Eur Arch Otorhinolaryngol 2003;260:186–94

IMS: National Disease & Therapeutic Index Audit, June 2005 (Adult Antibiotic Market, Oral Solids (excluding chewables)